Should Investors Hold Chemed Stock in Their Portfolio Now?
CHE stays on investors' radar due to its robust prospects in the VITAS business and the resilient Roto-Rooter arm.
Chemed Stock Hurt by Roto-Rooter Softness, Macro Issues Dent Growth
The ongoing global economic conditions, such as general labor, supply chain and inflationary pressure, along with political and regulatory developments, are escalating expenses for CHE.
Chemed Corporation (CHE) Q3 2024 Earnings Call Transcript
Chemed Corporation (NYSE:CHE ) Q3 2024 Earnings Conference Call October 30, 2024 10:00 AM ET Company Participants Holley Schmidt - Assistant Controller Kevin McNamara - President and Chief Executive Officer Mike Witzeman - Chief Financial Officer Nick Westfall - Chairman and Chief Executive Officer, VITAS Healthcare Corporation Conference Call Participants Ben Hendrix - RBC Capital Markets Joanna Gajuk - Bank of America Operator Good day and thank you for standing by. Welcome to the Chemed Corporation Third Quarter 2024 Earnings Conference Call.
CHE Misses on Q3 Earnings, Lowers '24 EPS View, Stock Up
Chemed's VITAS segment reports impressive revenue growth and margin expansion for the third quarter of 2024.
Chemed (CHE) Lags Q3 Earnings and Revenue Estimates
Chemed (CHE) came out with quarterly earnings of $5.64 per share, missing the Zacks Consensus Estimate of $5.76 per share. This compares to earnings of $5.32 per share a year ago.
Reasons to Retain Chemed Stock in Your Portfolio Now
Investors feel optimistic about CHE's strong growth prospects in the VITAS business. Yet, unfavorable macroeconomic conditions are concerning.
Final Trades: Exxon, Chemed, Las Vegas Sands and the IEO
The Investment Committee give you their top stocks to watch for the second half.
Why Chemed (CHE) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Chemed (CHE) Up 5.7% Since Last Earnings Report: Can It Continue?
Chemed (CHE) reported earnings 30 days ago. What's next for the stock?
Chemed Remains A Buy On Long-Term Economics
Chemed continues to present with exceptional economic characteristics now at depressed valuations vs. history. The business is highly profitable and earns high rates of return on all the capital that's been employed into its operations. Management has an extensive reinvestment runway to redeploy surplus funds and grow the intrinsic worth of the business.
Here's Why Chemed (CHE) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Ways to Play the Long-Term Care Crisis in 2024
Morningstar.com published an interesting piece in July about the long-term health care crisis. It pointed out that Americans paid out $245 billion for long term care to paid caregivers, nursing homes and other forms of paid assistance.
